文献速递免疫规划传染病防控与疫情报告

编码Gc蛋白的mRNA疫苗对发热伴血小板减少综合征病毒提供完全保护

The mRNA vaccine encoding Gc protein confers complete protection against severe fever with thrombocytopaenia syndrome virus.
PubMed 文献 · Vaccine · 2025-08-21

本研究开发了编码糖蛋白C(Gc)基因的SFTSV mRNA疫苗,在C57BL/6和IFNAR-/-小鼠中诱导平衡的TH1/TH2免疫应答及细胞与体液免疫;1 μg mRNA疫苗在IFNAR-/-小鼠中对致死性SFTSV攻击(77,000 LD50)提供100%完全保护,免疫力至少持续六个月,被动转移抗体提供100%保护。

要点

  • 编码Gc基因的mRNA疫苗在C57BL/6和IFNAR-/-小鼠中诱导平衡的TH1/TH2免疫应答。
  • 1 μg mRNA疫苗在IFNAR-/-小鼠中对致死性SFTSV攻击(77,000 LD50)提供100%完全保护。
  • 疫苗诱导的免疫力至少持续六个月,被动转移抗体提供100%保护。

核心结论

  • 编码Gc蛋白的mRNA疫苗在IFNAR-/-小鼠中对致死性SFTSV攻击提供100%完全保护,并诱导至少六个月的持久免疫。
  • 被动转移抗体提供100%保护,提示体液免疫在抵抗SFTSV攻击中起关键作用。

研究设计与样本

  • 研究开发了编码糖蛋白C(Gc)基因的SFTSV mRNA疫苗,表达蛋白实现N-连接糖基化。
  • 在C57BL/6和IFNAR-/-小鼠中评估疫苗诱导的免疫应答及对致死性SFTSV攻击(77,000 LD50)的保护效果。

主要发现

  • 疫苗诱导平衡的TH1/TH2免疫应答,并在C57BL/6和IFNAR-/-小鼠中 elicits 高水平细胞免疫和体液免疫。
  • 1 μg mRNA疫苗在IFNAR-/-小鼠中对致死性SFTSV感染(77,000 LD50)提供100%完全保护。
  • 疫苗候选诱导持久免疫,对SFTSV提供至少六个月的保护。
  • 被动转移试验中抗体提供100%保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Severe fever with thrombocytopaenia syndrome virus (SFTSV), an emerging tick-borne pathogen, causes haemorrhagic fever in infected patients and is associated with a high mortality rate in humans. The imperative need for vaccines against this lethal virus is underscored by a lack of effective preventive measures. The results of this study yield notable advancements: the successful development of an SFTSV mRNA vaccine encoding the glycoprotein C (Gc) gene, achieving N-linked glycosylation in the expressed protein. This vaccination regimen induced a balanced TH1/TH2 immune response and elicited robust levels of both cellular and humoral immunity in C57BL/6 and IFNAR-/- mice. The results of the present study demonstrate that immunization with 1 μg mRNA vaccine provides complete protection (100 %) against lethal SFTSV infection (77,000 LD50) in IFNAR-/- mice. Moreover, the vaccine candidate induces long-lasting immunity and confers protection against SFTSV for at least six months. Notably, the antibody provides 100 % protection according to passive transfer assays, suggesting that humoral immunity plays a crucial role in resisting SFTSV challenge. These findings present a promising stride forward in the quest for an effective vaccine against SFTSV, highlighting the potential of the developed mRNA vaccine in conferring substantial immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang X, Zhang X, Lu J, et al. The mRNA vaccine encoding Gc protein confers complete protection against severe fever with thrombocytopaenia syndrome virus. Vaccine. 2025. PMID: 40845791. doi:10.1016/j.vaccine.2025.127631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。